Jeffrey Allen Willard - 28 Sep 2026 Form 4 Insider Report for PETMED EXPRESS INC (PETS)

Reporting relationship: CEO and President, Director
Issuer ticker: PETS
Reported as of: 28 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Sep 2026, 16:36:14 UTC
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Allen Willard

Key filing fact

Jeffrey Allen Willard filed Form 4 for PETMED EXPRESS INC (PETS) on 29 Sep 2026.

Key facts

This page summarizes Jeffrey Allen Willard's Form 4 filing for PETMED EXPRESS INC (PETS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Sep 2026, 16:36.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002155835 Primary reporting owner

Willard Jeffrey Allen

Relationship: CEO and President, Director
Address: C/O PETMED EXPRESS, INC., 420 SOUTH CONGRESS AVENUE, DELRAY BEACH
Signature: /s/ Jeffrey Allen Willard
Signature date: 29 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PETS transaction

Common Stock

Award

Transaction value
Shares: +250,000
Change %
Price: $0.000000^*
Shares after: 250,000
Date: 28 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PETS transaction Derivative

Performance Share Units

Award

Transaction value
Shares: +250,000
Change %
Price: $0.000000^*
Shares after: 250,000
Date: 28 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Inducement Incentive Plan that will vest as to one-third of the granted shares on each of the first three anniversaries of the grant date, subject to continued employment and subject to accelerated vesting upon death, disability, a change of control, or certain terminations of employment.

Footnote F2

Performance Share Units ("PSUs") granted pursuant to the 2024 Inducement Incentive Plan. Each PSU represents a contingent right to receive one share of the Company's Common Stock if predetermined levels of the Company's total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over a three-year performance period ending on September 27, 2029.